Arrowhead Research Corp. (NASDAQ:ARWR) – Stock analysts at Jefferies Group decreased their FY2020 EPS estimates for Arrowhead Research Corp. in a research report issued to clients and investors on Wednesday. Jefferies Group analyst E. Yang now expects that the brokerage will post earnings of $2.09 per share for the year, down from their prior forecast of $2.16. Jefferies Group has a “Hold” rating and a $5.00 price target on the stock.

ARWR has been the topic of several other reports. Cantor Fitzgerald started coverage on Arrowhead Research Corp. in a report on Wednesday, August 17th. They set a “buy” rating and a $15.00 target price on the stock. William Blair initiated coverage on Arrowhead Research Corp. in a research report on Friday, August 19th. They set an “outperform” rating for the company. Chardan Capital restated a “buy” rating and set a $10.00 price objective on shares of Arrowhead Research Corp. in a research report on Wednesday, September 7th. Finally, Piper Jaffray Cos. dropped their price objective on Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating for the company in a research report on Wednesday, August 10th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Arrowhead Research Corp. currently has a consensus rating of “Buy” and a consensus price target of $9.81.

Earnings History and Estimates for Arrowhead Research Corp. (NASDAQ:ARWR)

Arrowhead Research Corp. (NASDAQ:ARWR) opened at 4.18 on Friday. The stock’s 50 day moving average price is $6.44 and its 200 day moving average price is $6.18. Arrowhead Research Corp. has a 52-week low of $3.07 and a 52-week high of $8.22. The firm’s market capitalization is $253.94 million.

Several institutional investors have recently modified their holdings of the company. BlackRock Fund Advisors increased its position in shares of Arrowhead Research Corp. by 6.4% in the third quarter. BlackRock Fund Advisors now owns 2,490,393 shares of the company’s stock worth $18,304,000 after buying an additional 150,805 shares during the period. Vanguard Group Inc. increased its position in shares of Arrowhead Research Corp. by 2.6% in the second quarter. Vanguard Group Inc. now owns 2,446,346 shares of the company’s stock worth $13,015,000 after buying an additional 62,229 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of Arrowhead Research Corp. by 11.1% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,715,221 shares of the company’s stock worth $12,607,000 after buying an additional 171,165 shares during the period. JPMorgan Chase & Co. increased its position in shares of Arrowhead Research Corp. by 0.9% in the third quarter. JPMorgan Chase & Co. now owns 1,492,159 shares of the company’s stock worth $10,967,000 after buying an additional 12,809 shares during the period. Finally, State Street Corp increased its position in shares of Arrowhead Research Corp. by 1.3% in the second quarter. State Street Corp now owns 957,536 shares of the company’s stock worth $5,096,000 after buying an additional 12,676 shares during the period. Institutional investors own 34.00% of the company’s stock.

In other news, CFO Kenneth Allen Myszkowski sold 6,900 shares of the firm’s stock in a transaction dated Tuesday, August 23rd. The stock was sold at an average price of $8.00, for a total transaction of $55,200.00. Following the completion of the transaction, the chief financial officer now directly owns 128,789 shares in the company, valued at $1,030,312. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Douglas B. Given sold 12,000 shares of the firm’s stock in a transaction dated Friday, October 14th. The stock was sold at an average price of $6.72, for a total value of $80,640.00. The disclosure for this sale can be found here. 3.90% of the stock is owned by company insiders.

About Arrowhead Research Corp.

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

5 Day Chart for NASDAQ:ARWR

Receive News & Stock Ratings for Arrowhead Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Research Corp. and related stocks with our FREE daily email newsletter.